Dolutegravir Resistance in Malawi’s National HIV Treatment Program

Domain:

healthcare

Creator:

JoeChiLysHop

Publisher:

Oxf

Host:

Abstract Dolutegravir HIV drug resistance (HIVDR) data from Africa remain sparse. We reviewed HIVDR results of Malawians on dolutegravir-based antiretroviral therapy (November 2020–September 2021). Of 6462 eligible clients, 33 samples were submitted to South Africa, 27 were sequenced successfully, and 8 (30%) had dolutegravir HIVDR. Malawi urgently requires adequate HIVDR testing capacity.

Visit

doi.org

Licenses

https://creativecommons.org/licenses/by-nc-nd/4.0/

The National Evaluation of Malawi’s PMTCT Program (NEMAPP) study: 24‐month HIV‐exposed infant outcomes from a prospective cohort study

Abstract Objectives Data on long‐term HIV‐free survival in breastfeeding, HIV‐exposed infants (HE

The impact of migrant-inclusive policy on Botswana’s universal HIV treatment program: a retrospective analysis of the national HIV treatment program data (2016–2022)

Background Botswana has made substantial progress toward the Joint United Nati

Low Prevalence of Pre-Treatment and Acquired Drug Resistance to Dolutegravir among Treatment Naïve Individuals Initiating on Tenofovir, Lamivudine and Dolutegravir in Zimbabwe

Dolutegravir (DTG) use in combination with tenofovir and lamivudine (TLD) is scaling up in Africa. H

Table 1_The impact of migrant-inclusive policy on Botswana’s universal HIV treatment program: a retrospective analysis of the national HIV treatment program data (2016–2022).docx

Background

Botswana has made substantial progress toward the Joint United Nations Programme on Hum

Treatment optimisation with dolutegravir-based antiretroviral treatment for children and adolescents with HIV

As of 2024, an estimated 2.4 million children and adolescents were living with HIV. While new infect

Weight Gain Among Treatment-Naïve Persons With HIV Receiving Dolutegravir in Kenya

Background: Several recent studies have linked integrase strand transfer inhibitors (I